2022
Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial
Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology 2022, 163: 608-619. PMID: 35679950, DOI: 10.1053/j.gastro.2022.05.055.Peer-Reviewed Original ResearchConceptsEradication rateHelicobacter pylori infectionTriple therapyDual therapyPylori infectionProton pump inhibitor-based triple therapyTreatment-emergent adverse eventsInhibitor-based triple therapyPotassium-competitive acid blockerEfficacy of vonoprazanH pylori eradicationPhase 3 trialOverall study populationAmoxicillin-resistant strainsClarithromycin-resistant strainsH pylori infectionTreatment-naïve adultsPylori eradicationAdverse eventsSecondary outcomesPrimary outcomeStandard treatmentClinical trialsStudy populationAcid blocker
2016
The Toronto Helicobacter pylori Consensus in Context
Graham DY, Laine L. The Toronto Helicobacter pylori Consensus in Context. Gastroenterology 2016, 151: 9-12. PMID: 27215659, PMCID: PMC6910198, DOI: 10.1053/j.gastro.2016.05.009.Commentaries, Editorials and Letters
2014
Low Adherence to Helicobacter pylori Testing in Hospitalized Patients with Bleeding Peptic Ulcer Disease
Kim JJ, Lee JS, Olafsson S, Laine L. Low Adherence to Helicobacter pylori Testing in Hospitalized Patients with Bleeding Peptic Ulcer Disease. Helicobacter 2014, 19: 98-104. PMID: 24617668, DOI: 10.1111/hel.12114.Peer-Reviewed Original ResearchConceptsH. pylori testingProportion of patientsIndex hospitalizationHospitalized patientsConsecutive hospitalized patientsPeptic ulcer diseaseHelicobacter pylori testingInitial endoscopyUlcer diseaseSerologic testingSingle centerEndoscopy databaseSociety guidelinesGastric ulcerLow adherencePatientsUlcersMultivariate analysisHelicobacter pyloriHospitalizationDirect testingBiopsyTestingEndoscopyPylori
2006
Effect of frequent dosing of an oral proton pump inhibitor on intragastric pH
PAIS SA, NATHWANI RA, DHAR V, NOWAIN A, LAINE L. Effect of frequent dosing of an oral proton pump inhibitor on intragastric pH. Alimentary Pharmacology & Therapeutics 2006, 23: 1607-1613. PMID: 16696810, DOI: 10.1111/j.1365-2036.2006.02933.x.Peer-Reviewed Original ResearchConceptsProton pump inhibitorsPump inhibitorsOral proton pump inhibitorsDoses of lansoprazoleFrequent oral dosingLansoprazole plasma concentrationHelicobacter pylori statusCYP2C19 statusOral lansoprazolePylori statusOvernight fastOral dosingPlasma concentrationsFrequent dosingHealthy volunteersClot formationTime pointsLansoprazoleMean proportionDosingInhibitorsSubjectsStatusPatientsPeriodGI Risk and Risk Factors of NSAIDs
Laine L. GI Risk and Risk Factors of NSAIDs. Journal Of Cardiovascular Pharmacology 2006, 47: s60-s66. PMID: 16785831, DOI: 10.1097/00005344-200605001-00011.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnti-Inflammatory Agents, Non-SteroidalGastrointestinal DiseasesHelicobacter InfectionsHelicobacter pyloriHumansRisk FactorsConceptsNonsteroidal anti-inflammatory drugsUpper GI eventsClinical eventsNSAID useGI eventsRisk factorsMultiple nonsteroidal anti-inflammatory drugsNon-NSAID analgesicsUpper GI symptomsUse of coxibsUpper gastrointestinal complicationsUse of corticosteroidsRegular NSAID useImportant risk factorLowest effective doseAnti-inflammatory drugsGastrointestinal complicationsGI symptomsAnnual incidenceRisk stratificationGI riskRelative riskPrior historyEffective doseOlder age
2005
The effect of GI bleeding on Helicobacter pylori diagnostic testing: a prospective study at the time of bleeding and 1 month later
Laine LA, Nathwani RA, Naritoku W. The effect of GI bleeding on Helicobacter pylori diagnostic testing: a prospective study at the time of bleeding and 1 month later. Gastrointestinal Endoscopy 2005, 62: 853-859. PMID: 16301025, DOI: 10.1016/j.gie.2005.09.019.Peer-Reviewed Original ResearchConceptsH pylori densityAcute GI bleedingInflammatory cell infiltrationH pyloriGI bleedingHistologic examinationCohort studyCell infiltrationDiagnostic testingBlinded histologic examinationH pylori testingAcute variceal bleedingProspective cohort studyUrban county hospitalProton pump inhibitorsTime of bleedingRapid urease testingVariceal bleedingCase seriesEndoscopic biopsyProspective studyPump inhibitorsBiopsy specimensUrease testingCounty Hospital
2003
Bismuth-Based Quadruple Therapy Using a Single Capsule of Bismuth Biskalcitrate, Metronidazole, and Tetracycline Given With Omeprazole Versus Omeprazole, Amoxicillin, and Clarithromycin for Eradication of Helicobacter pylori in Duodenal Ulcer Patients: A Prospective, Randomized, Multicenter, North American Trial
Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-Based Quadruple Therapy Using a Single Capsule of Bismuth Biskalcitrate, Metronidazole, and Tetracycline Given With Omeprazole Versus Omeprazole, Amoxicillin, and Clarithromycin for Eradication of Helicobacter pylori in Duodenal Ulcer Patients: A Prospective, Randomized, Multicenter, North American Trial. The American Journal Of Gastroenterology 2003, 98: ajg2003137. PMID: 12650788, DOI: 10.1111/j.1572-0241.2003.t01-1-07288.x.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAmoxicillinAnti-Bacterial AgentsAnti-Ulcer AgentsCapsulesDrug Administration ScheduleDrug CombinationsDrug Therapy, CombinationDuodenal UlcerFemaleHelicobacter InfectionsHelicobacter pyloriHumansMaleMetronidazoleMiddle AgedNorth AmericaOmeprazoleOrganometallic CompoundsTetracyclineTreatment OutcomeConceptsUrea breath testQuadruple therapyDuodenal ulcerBreath testNegative urea breath testTreat eradication ratesH. pylori eradicationActive duodenal ulcerDuodenal ulcer patientsNorth American trialsClarithromycin-resistant strainsActive-controlled trialHelicobacter pylori infectionTreatment of patientsMetronidazole-resistant strainsCapsules q.OAC patientsOAC regimenEradication ratePylori eradicationTriple therapyAdverse eventsUlcer patientsPylori infectionMetronidazole resistance
2002
Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies
Sugg J, Laine L. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. The American Journal Of Gastroenterology 2002, 97: 2992. PMID: 12492181, DOI: 10.1111/j.1572-0241.2002.07116.x.Peer-Reviewed Original ResearchMeSH KeywordsEsophagitisGastroesophageal RefluxHelicobacter InfectionsHelicobacter pyloriHumansSeverity of Illness IndexConceptsPersistent H. pyloriErosive esophagitisGERD symptomsH. pyloriSymptomatic GERDPersistent infectionDouble-blind prospective studyDouble-blind prospective trialGastroesophageal reflux disease symptomsCompletion of therapyDuodenal ulcer diseaseGastroesophageal reflux diseaseHelicobacter pylori eradicationHelicobacter pylori therapyWorsening of symptomsEnd of therapyRapid urease testBlind prospective studyPylori eradicationPylori therapyReflux diseaseRegurgitation scoreProspective trialDuodenal ulcerUlcer diseaseStratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis
Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, Reicin A. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002, 123: 1006-1012. PMID: 12360461, DOI: 10.1053/gast.2002.36013.Peer-Reviewed Original ResearchConceptsUpper GI eventsClinical upper GI eventsSelective cyclooxygenase-2 inhibitorHigh-risk patientsGI eventsRisk factorsCyclooxygenase-2 inhibitorClinical characteristicsRheumatoid arthritisClinical eventsNonsteroidal anti-inflammatory drugsClinical GI eventsRisk of NSAIDUpper GI complicationsLow-risk patientsSevere rheumatoid arthritisPatients' clinical characteristicsRheumatoid arthritis patientsAbsolute risk reductionLow-risk subgroupsAnti-inflammatory drugsIndividual risk factorsRisk of eventsGI complicationsNonselective NSAIDs
2001
Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials.
Laine L, Schoenfeld P, Fennerty M. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Annals Of Internal Medicine 2001, 134: 361-9. PMID: 11242496, DOI: 10.7326/0003-4819-134-5-200103060-00008.Peer-Reviewed Original ResearchConceptsH. pylori eradication therapyNonulcer dyspepsiaPylori eradication therapyEradication therapyControl therapyOdds ratioH. pyloriHelicobacter pyloriDefinition of dyspepsiaDuplicate data extractionEnd of therapyH. pylori infectionAnalysis of trialsPylori infectionCombination therapyMethodologic qualityTreatment successDyspepsiaPersistent infectionReference listsTherapyPatientsStudy designPrimary investigatorPylori
2000
Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials
Laine L, Fennerty M, Osato M, Sugg J, Suchower L, Probst P, Levine J. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. The American Journal Of Gastroenterology 2000, 95: ajg20001583. PMID: 11151867, DOI: 10.1111/j.1572-0241.2000.03349.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmoxicillinClarithromycinDouble-Blind MethodDrug Administration ScheduleDrug Resistance, MicrobialDrug Therapy, CombinationDuodenal UlcerEsomeprazoleFemaleHelicobacter InfectionsHelicobacter pyloriHumansMaleMiddle AgedPenicillin ResistancePenicillinsProspective StudiesProtein Synthesis InhibitorsProton Pump InhibitorsConceptsEradication rateClarithromycin resistanceDaily esomeprazoleTriple therapyDuodenal ulcerProton pump inhibitor-based triple therapyTen-day triple therapyHelicobacter pylori eradication therapyEmergent resistanceH. pylori-positive patientsInhibitor-based triple therapyDouble-blind trialTreat eradication ratesCompletion of therapyPylori eradication therapyPylori-positive patientsSeparate randomized trialsAntibiotic resistanceDaily amoxicillinUS multicenterEradication therapyRandomized trialsHelicobacter pyloriTherapyEsomeprazoleEndoscopic biopsy requirements for post-treatment diagnosis of Helicobacter pylori
Laine L, Sugg J, Suchower L, Neil G. Endoscopic biopsy requirements for post-treatment diagnosis of Helicobacter pylori. Gastrointestinal Endoscopy 2000, 51: 664-669. PMID: 10840297, DOI: 10.1067/mge.2000.105776.Peer-Reviewed Original ResearchConceptsTriple therapyH pylori infectionBody biopsyAntral biopsiesHistologic examinationPylori infectionBiopsy testsDiagnostic yieldProton pump inhibitor-based triple therapyMulticenter double-blind trialInhibitor-based triple therapyDouble-blind trialPost-treatment sensitivityTriple therapy groupDual antibiotic therapyH pylori statusRapid urease testEndoscopic biopsy testsPost-treatment diagnosisHelicobacter pylori diagnosisPretreatment sensitivityEradication therapyUntreated patientsAntibiotic therapyDual therapy
1999
Fingerstick Helicobacter pylori antibody test: better than laboratory serological testing?
Faigel D, Vartan G, Knigge K, Laine L, Fennerty M, Margaret N, Marquis S. Fingerstick Helicobacter pylori antibody test: better than laboratory serological testing? The American Journal Of Gastroenterology 1999, 94: ajg1999810. PMID: 10606304, DOI: 10.1111/j.1572-0241.1999.01510.x.Peer-Reviewed Original ResearchA multicentre evaluation of the laser assisted ratio analyser (LARA): a novel device for measurement of 13CO2 in the 13C‐urea breath test for the detection of Helicobacter pylori infection
Cave DR, van Zanten S, Carter E, Halpern EF, Klein S, Prather C, Stolte M, Laine L. A multicentre evaluation of the laser assisted ratio analyser (LARA): a novel device for measurement of 13CO2 in the 13C‐urea breath test for the detection of Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics 1999, 13: 747-752. PMID: 10383503, DOI: 10.1046/j.1365-2036.1999.00534.x.Peer-Reviewed Original ResearchOnce-daily therapy for H. pylori infection: a randomized comparison of four regimens
Laine L, Estrada R, Trujillo M, Cheybani K, Yeramian P, Smith S, Neil G. Once-daily therapy for H. pylori infection: a randomized comparison of four regimens. The American Journal Of Gastroenterology 1999, 94: 962. PMID: 10201465, DOI: 10.1111/j.1572-0241.1999.995_r.x.Peer-Reviewed Original ResearchConceptsH. pylori infectionEradication ratePylori infectionExtended-release formulationDaily therapyBreath testDaily triple therapyHigh-dose omeprazoleTreat eradication ratesCompletion of therapyHelicobacter pylori infectionRepeat breath testStudy medicationTriple therapyEndoscopic biopsyRandomized comparisonLack of complianceTherapyPilot studyInfectionFurther studiesClarithromycinOmamDaysSubjectsHelicobacter pylori: drowning in a pool of blood?
Laine L, Cohen H. Helicobacter pylori: drowning in a pool of blood? Gastrointestinal Endoscopy 1999, 49: 398-402. PMID: 10049431, DOI: 10.1016/s0016-5107(99)70024-6.Commentaries, Editorials and Letters
1998
Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials
Laine L, Suchower L, Frantz J, Connors A, Neil G. Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. The American Journal Of Gastroenterology 1998, 93: ajg1998488. PMID: 9820381, DOI: 10.1111/j.1572-0241.1998.00602.x.Peer-Reviewed Original ResearchConceptsDuodenal ulcer diseaseTriple therapyEradication rateUlcer diseaseH. pylori-infected patientsDaily triple therapyDays of omeprazoleDuodenal ulcer historyProtocol cure ratesProtocol eradication ratesTreat eradication ratesHelicobacter pylori eradicationPylori-infected patientsOAC patientsStudy medicationTreat populationUlcer historyPylori eradicationStudy drugAdverse eventsTwice DailyControlled TrialsDuodenal ulcerCure ratePatientsEvaluation of the FlexSure HP whole blood antibody test for diagnosis of Helicobacter pylori infection
Sadowski D, Cohen H, Laine L, Greenberg P, Goldstein J, Mihalov M, Cutler A. Evaluation of the FlexSure HP whole blood antibody test for diagnosis of Helicobacter pylori infection. The American Journal Of Gastroenterology 1998, 93: ajg1998490. PMID: 9820383, DOI: 10.1111/j.1572-0241.1998.00604.x.Peer-Reviewed Original ResearchConceptsHelicobacter pylori infectionRapid urease testPylori infectionWhole blood testH. pyloriWhole bloodBlood testsUrease testPositive rapid urease testBlood antibody testH. pylori infectionProton pump inhibitorsH. pylori diagnosisDetection of antibodiesUpper endoscopyStudy enrollmentPump inhibitorsGastric biopsiesIgG antibodiesSerum testAntibody testOffice testsAntral tissueBacterial infectionsPatientsEffect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori.
Laine L, Estrada R, Trujillo M, Knigge K, Fennerty MB. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Annals Of Internal Medicine 1998, 129: 547-50. PMID: 9758575, DOI: 10.7326/0003-4819-129-7-199810010-00007.Peer-Reviewed Original ResearchConceptsUrea breath testProton pump inhibitor therapyBreath test resultsProton pump inhibitorsBreath testInhibitor therapyH. pyloriDiagnostic testingCompletion of therapyProportion of patientsNegative breath test resultH. pylori infectionUrea breath test resultsLansoprazole therapyFalse-negative resultsGastroenterology clinicPylori infectionPatientsHelicobacter pyloriTherapyDuration of conversionPyloriPositive resultsLansoprazoleDaysHas the impact of helicobacter pylori therapy on ulcer recurrence in the united states been overstated?
Laine L, Hopkins R, Girardi L. Has the impact of helicobacter pylori therapy on ulcer recurrence in the united states been overstated? The American Journal Of Gastroenterology 1998, 93: 1409. PMID: 9732917, DOI: 10.1111/j.1572-0241.1998.452_a.x.Peer-Reviewed Original ResearchMeSH KeywordsDouble-Blind MethodDuodenal UlcerHelicobacter InfectionsHelicobacter pyloriHumansOdds RatioRandomized Controlled Trials as TopicRecurrenceConceptsH. pylori eradicationH. pylori therapyUlcer recurrencePylori eradicationPylori therapyH. pylori cureNon-NSAID ulcersCompletion of therapyHelicobacter pylori therapyUse of NSAIDsDuodenal ulcer patientsNorth American trialsUlcer recurrence rateHigh methodological qualityEndoscopic biopsy testsReview of abstractsEndoscopic followUlcer patientsDuodenal ulcerRelevant trialsRecurrence rateStudy inclusionOdds ratioCommon odds ratioMethodological quality